In this interview series called “I Survived Cancer and Here Is How I Did It”, Savio P. Clemente talks to cancer survivor Dave Latham to share his story, in order to offer hope and provide strength to people who are being impacted by cancer today.
Co-leader of Stand Up To Cancer’s Colorectal Cancer Health Equity Dream, Dr. Folasade May, is honored in Fierce Healthcare’s 2022 Women of Influence Awards.
Owen Munday, 18-year-old student in Canada, shares his survivorship story with a clinical trial for a rare form of cancer.
Lisa Lewis, Director, Diversity, Equity, & Inclusion in Clinical Trials – Oncology at Janssen Research & Development speaks on SU2C sponsorship to increase the participation of patients from medically underserved communities in oncology early phase clinical trials.
Dr Velcheti discusses planned research into whether mobile technology services can improve patient outcomes for underserved and underrepresented patient populations.
Katie Couric announced Wednesday that she was diagnosed with Stage 1 breast cancer in June after missing her annual mammogram. TODAY’s Sheinelle Jones reports on the message Couric released encouraging people to get screened.
The American Association for Cancer Research (AACR) honored numerous esteemed individuals and organizations during the AACR 115th Anniversary Event in Washington, D.C., on Wednesday, September 21, for their outstanding achievements in advancing cancer research. More than 250 guests from the cancer research field attended the event hosted by Margaret Foti, PhD, MD (hc), Chief Executive Officer of the AACR.
Stand Up To Cancer (SU2C) brought together local health organization Providence St. John’s/Santa Monica, UCLA Health, and community organizations in South and East Lost Angeles to proactively address ongoing disparities in screening and treatment of colorectal cancers, successfully increasing screening rates to 80% within the SU2C Zones.
Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer® (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.
